A recent study including Zack Meisel was featured by Penn LDI for illuminating that only 1 in 3 pregnant individuals who were eligible for an evidence-based buprenorphine treatment actually received it, which contributes to maternal mortality.
A recent study including Zack Meisel was featured by Penn LDI for illuminating that only 1 in 3 pregnant individuals who were eligible for an evidence-based buprenorphine treatment actually received it, which contributes to maternal mortality.
